222 related articles for article (PubMed ID: 15872045)
21. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors.
Devi GR; Beer TM; Corless CL; Arora V; Weller DL; Iversen PL
Clin Cancer Res; 2005 May; 11(10):3930-8. PubMed ID: 15897595
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.
Deas TS; Binduga-Gajewska I; Tilgner M; Ren P; Stein DA; Moulton HM; Iversen PL; Kauffman EB; Kramer LD; Shi PY
J Virol; 2005 Apr; 79(8):4599-609. PubMed ID: 15795246
[TBL] [Abstract][Full Text] [Related]
23. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
24. Antibiotic-free bacterial strain selection using antisense peptide nucleic acid.
Dryselius R; Nekhotiaeva N; Nielsen PE; Good L
Biotechniques; 2003 Nov; 35(5):1060-4. PubMed ID: 14628680
[TBL] [Abstract][Full Text] [Related]
25. A genome rearrangement has orphaned the Escherichia coli K-12 AcpT phosphopantetheinyl transferase from its cognate Escherichia coli O157:H7 substrates.
De Lay NR; Cronan JE
Mol Microbiol; 2006 Jul; 61(1):232-42. PubMed ID: 16824108
[TBL] [Abstract][Full Text] [Related]
26. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models.
Burrer R; Neuman BW; Ting JP; Stein DA; Moulton HM; Iversen PL; Kuhn P; Buchmeier MJ
J Virol; 2007 Jun; 81(11):5637-48. PubMed ID: 17344287
[TBL] [Abstract][Full Text] [Related]
27. Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers.
Ghosh C; Iversen PL
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):263-74. PubMed ID: 10984120
[TBL] [Abstract][Full Text] [Related]
28. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo.
Moulton HM; Fletcher S; Neuman BW; McClorey G; Stein DA; Abes S; Wilton SD; Buchmeier MJ; Lebleu B; Iversen PL
Biochem Soc Trans; 2007 Aug; 35(Pt 4):826-8. PubMed ID: 17635157
[TBL] [Abstract][Full Text] [Related]
29. Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin.
Pannier AK; Arora V; Iversen PL; Brand RM
Int J Pharm; 2004 May; 275(1-2):217-26. PubMed ID: 15081152
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers.
Stein DA; Skilling DE; Iversen PL; Smith AW
Antisense Nucleic Acid Drug Dev; 2001 Oct; 11(5):317-25. PubMed ID: 11763348
[TBL] [Abstract][Full Text] [Related]
31. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice.
Vingsbo Lundberg C; Vaara T; Frimodt-Møller N; Vaara M
J Antimicrob Chemother; 2010 May; 65(5):981-5. PubMed ID: 20233777
[TBL] [Abstract][Full Text] [Related]
32. Bactericidal antisense effects of peptide-PNA conjugates.
Good L; Awasthi SK; Dryselius R; Larsson O; Nielsen PE
Nat Biotechnol; 2001 Apr; 19(4):360-4. PubMed ID: 11283595
[TBL] [Abstract][Full Text] [Related]
33. Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells.
Devi GR
Methods Mol Biol; 2009; 542():351-61. PubMed ID: 19565912
[TBL] [Abstract][Full Text] [Related]
34. Five-step process for screening antisense compounds for efficacy: gene target IL-12Rb2.
Marshall NB; Hauck LL; Mourich DV
Methods Mol Biol; 2011; 764():153-68. PubMed ID: 21748639
[TBL] [Abstract][Full Text] [Related]
35. Antisense PNA accumulates in Escherichia coli and mediates a long post-antibiotic effect.
Nikravesh A; Dryselius R; Faridani OR; Goh S; Sadeghizadeh M; Behmanesh M; Ganyu A; Klok EJ; Zain R; Good L
Mol Ther; 2007 Aug; 15(8):1537-42. PubMed ID: 17534267
[TBL] [Abstract][Full Text] [Related]
36. By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.
Mitrpant C; Fletcher S; Iversen PL; Wilton SD
J Gene Med; 2009 Jan; 11(1):46-56. PubMed ID: 19006096
[TBL] [Abstract][Full Text] [Related]
37. Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection.
Smith AW; Iversen PL; O'Hanley PD; Skilling DE; Christensen JR; Weaver SS; Longley K; Stone MA; Poet SE; Matson DO
Am J Vet Res; 2008 Jan; 69(1):23-32. PubMed ID: 18167083
[TBL] [Abstract][Full Text] [Related]
38. Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism.
Arora V; Cate ML; Ghosh C; Iversen PL
Drug Metab Dispos; 2002 Jul; 30(7):757-62. PubMed ID: 12065433
[TBL] [Abstract][Full Text] [Related]
39. Host defence and bacterial growth in fosfomycin-treated peritonitis. Experimental observations in pigs.
Berglund JE; Andåker L; Skau T; Nyström PO
Acta Chir Scand; 1990 Aug; 156(8):529-36. PubMed ID: 2239053
[TBL] [Abstract][Full Text] [Related]
40. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells.
Youngblood DS; Hatlevig SA; Hassinger JN; Iversen PL; Moulton HM
Bioconjug Chem; 2007; 18(1):50-60. PubMed ID: 17226957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
